BioM AG is a consultancy and investment company that is independent of the cluster management agency BioM GmbH. Its head office is located at Martinsried in the heart of the biotech cluster.
All information on the Munich Biotech Region and the Leading-Edge Cluster m4 - Personalized Medicine and Targeted Therapies. Cluster management is handled by BioM GmbH.
The network of Bavarian biotech regions comprises all the research institutions and companies operating in the life science sector and is coordinated by BioM GmbH.
Made in Munich: Amgen heading for "Bite" approval
The American biotech giant Amgen has submitted an application to the immunomolecule blinatumomab, a bispecific antibody which was and is developed in Munich.
4th Munich Biomarker Conference - early bird discount
Until October 10th, the 4th Munich Biomarker Conference on November 25th-26th, 2014 offers you an attractive early bird discount on the registration fee.
Have a look at the interdisciplinary programme of the European Networking Event for Personalized Medicine.
The congress with exhibition and partnering connects researchers and physicians...
New publication: European Biotechnology
"Horn Publishing" has launched a book some days ago in 2014 profiling the medical biotechnology industry throughout Europe. This hardcover book is a professional, high-quality publication, with informative editorials written by professional journalists.The book consists of segments devoted to selected countries from Austria, Germany,...
New radiopharmaceutic Center - Munich Großhadern Clinic in construction
Construction complete: the new Centre for Radiopharmacy - From diagnostics to theranostics.
The quiet introduction of another building complex remained unnoticed by many; however, its significance for a research location that counts as one of Europe’s top-ranking regions for therapy and diagnostics should not be underestimated: we are referring...
4th Munich Biomarker Conference - Program
Now the program is available for the European Networking Event for Personalized Medicine taking place in Munich, on November 25th-26th, 2014. The interdisciplinary conference brings together researchers and physicians with the biotech and pharma industry. Presentations by international experts highlight the following topics.
Nanotemper among the finalists of the “Deutscher Gründerpreis”
The finalists 2014 have been announced in the categories start-up and newcomer